# A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors

> **NCT00994071** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 9 (actual)

## Conditions studied

- Medulloblastoma
- Pontine Glioma
- Ependymoma
- Astrocytoma
- PNET

## Interventions

- **DRUG:** Temozolomide
- **DRUG:** ABT-888

## Key facts

- **NCT ID:** NCT00994071
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-22
- **Primary completion:** —
- **Final completion:** 2013-03-19
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00994071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00994071, "A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00994071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*